Dr. S is in a mental health group practice that includes one other psychiatrist, two psychologists, several social workers, and a nurse. She sees a variety of patients and diagnoses across the age range and socioeconomic spectrum. She is comfortable with both medication management and psychotherapy and does a large amount of collaborative treatment, prescribing medications for patients being seen for psychotherapy by others in her group. Now 5 years out of training, she feels comfortable with her practice pattern, but she knows that there have been some new developments in the field since she left training and sometimes feels frustrated that she does not always have time to keep up with things. Ms. D is a pharmaceutical representative promoting a well-established psychotropic drug that is widely used in the community and now has a new Food and Drug Administration (FDA)-approved indication and recently launched long-acting formulation. Dr. S agrees to meet with Ms. D to discuss the drug. Ms. D begins the meeting inquiring about Dr. S's family, vacation plans, and other personal topics. She offers notepads and pens with the company logo and proprietary drug name, as well as free samples of the new drug formulation and the older version of the medication. She presents peer-reviewed papers describing the company's studies of the efficacy and safety of the drug for its new indication and of its new formulation, accompanied by glossy charts highlighting the positive aspects of the drug. She invites Dr. S to a dinner program featuring a national speaker who will address the same issues. Dr. S is an ethical, competent, and conscientious physician, wanting to do the right thing for her patients and her own professional development. She wonders how she should handle each aspect of this visit.